Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Sep 11 - Sep 16
(PubMed) Ledezma E, DeSousa L, Jorquera A, et al
The 'Switch' is On: Proving the Viability of Oral Maintenance Therapy The ATTAIN-MAINTAIN study was a first-of-its-kind Phase 3 trial designed to answer a critical clinical question: can patients who have successfully lost weight on injectable GLP-1s (Wegovy or Zepbound) switch directly to an oral agent and maintain their results
The Phase 3 CagriSema program (REDEFINE 1, 2, REIMAGINE 2) capped cagrilintide at 2.4 mg per week
Methods We conducted two complementary analyses using subsets of Truveta Data
According to the FDA, these compounded products may use different active ingredients or contain impurities that could be harmful
In trials so far, this makes it the most effective injectable weight loss medication tested
